Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. - Wikidata - awgldk - TriplyDB

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

http://www.wikidata.org/entity/Q37253331

about

Is lipid signaling through cannabinoid 2 receptors part of a protective system?The choreography of neuroinflammation in Huntington's disease Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system Molecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations.Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis.Microglial Activation in the Pathogenesis of Huntington's Disease.Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy.The endocannabinoid system as a target for the treatment of neurodegenerative disease.Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice The role of endocannabinoids in pain modulation.Endocannabinoids prevent β-amyloid-mediated lysosomal destabilization in cultured neurons.Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.The therapeutic potential of cannabinoids for movement disorders.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection Molecular and cellular pathways as a target of therapeutic hypothermia: pharmacological aspect Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.Cannabinoid modulation of neuroinflammatory disorders.New insights on endocannabinoid transmission in psychomotor disorders.Cannabinoid agonists increase the interaction between β-Arrestin 2 and ERK1/2 and upregulate β-Arrestin 2 and 5-HT(2A) receptors.G-protein receptor kinase 5 regulates the cannabinoid receptor 2-induced up-regulation of serotonin 2A receptors.Modulating the endocannabinoid system in human health and disease--successes and failures The endocannabinoid system as a target for the treatment of motor dysfunction.The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.The endocannabinoid system as a target for the treatment of neuronal damage.Prospects for cannabinoid therapies in basal ganglia disorders.Cannabinoids, multiple sclerosis and neuroprotection.Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects.The endocannabinoid system: a putative role in neurodegenerative diseases.Cannabinoids: new promising agents in the treatment of neurological diseases.A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.Astrocytes in neurodegenerative disease.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.PET imaging of cannabinoid type 2 receptors with [11C]A-836339 did not evidence changes following neuroinflammation in rats.

P2860

Q24633122-3990F595-459F-4050-88CB-0CA66E6BEB0A Q26828403-00C87CE1-3A75-4F7E-A81F-C7EE19FF8B65 Q28073952-FC1BCC7D-6D4A-408E-ACE3-A3EA245E92E3 Q28277871-8BF1A31E-6066-44E4-9ADE-27AF990764AB Q28570135-7DD7CD74-5AEB-42E5-86B2-7E3D8424913B Q33624653-9ED71DCD-7922-443D-B1C0-49E0694C2E00 Q33664105-4244BFB2-995A-4535-A114-7C0068957B6A Q33746277-0E81228A-D7CD-4B8C-9729-F8A6A5381D67 Q33809556-DCE8D0B5-A976-4035-807D-892FE7A3216A Q33847549-3E9DF924-CC0F-48F7-8FDD-771C4C368287 Q34098196-AE15490C-FE52-437A-A25A-9E806FF7CB67 Q34203193-ED23DB44-8D5C-486B-9028-83DD1A8E7EC4 Q34320270-A9019C51-6BA0-43E9-96D7-14C55E3D01CF Q34352311-EDCF3ED5-571F-48C9-BAEA-177699073137 Q34403197-70143428-9826-4BA0-9E8B-F0CDC933FD5E Q34440282-181E3173-6D35-4705-88D9-425D71D29A1C Q35171113-2B49B4F4-96E4-4539-B401-06CCAF898110 Q35499568-A5C53415-0ACE-47BD-ADF4-D4D97047FEB6 Q35778735-7D50D9AD-CE79-4522-8394-CD8F83129542 Q36056302-6FD2E14A-9F85-4740-8A4C-93FF716A51E3 Q36067324-FC0B9EA3-371D-4621-BDA2-EACF2A77C789 Q36074595-51CF647B-0D46-4E40-B30E-FD9E1E27552A Q36582466-2F1381E4-4A60-409B-9181-4E1934A92B6B Q36890617-F6F1C953-36E3-40C4-8877-47096718BF73 Q36933683-695E0AF2-42FA-49D7-9965-38BC2A5FA709 Q37394164-FB8B31DC-A9AB-4E13-94FD-2C05E3E7BE74 Q37577451-E94DE5E1-6671-4F00-B6D7-D6236716D6E5 Q37637769-DE9283B5-9010-401A-AD0E-7E8B2F85BB45 Q37709370-14948E48-76F8-41F2-A43D-23F9B7215195 Q37872326-997B8F34-216B-4972-A067-02953BFFFE18 Q37960199-695A2083-FE5F-4D16-A704-FE49A825150E Q38012845-26CB1CC9-AC4F-4EFB-8299-BB7DA17EBBF9 Q38072364-384D0E7E-D827-446A-BDBA-8C89162B46FE Q38223774-553CCE0D-CBAB-43A7-9340-9C0AA937CCC3 Q38269376-5AD79FA3-E472-4295-9A8F-96CFAFE70928 Q38392800-F44B9F50-052A-42A7-BA1F-22A441BC5DA8 Q38422519-180FB69E-677B-4108-94D7-932B42A5A805 Q38563981-A05BE35C-B0A1-472C-A8D0-23CF285752CC Q38684679-95927971-714A-4387-98F8-C8FFDC6C102B Q38771463-C7120BED-8204-4A37-9F5C-91D34EDCD296

P2860

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

http://www.wikidata.org/entity/Q37253331

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cannabinoid CB2 receptor agoni ...... ance for Huntington's disease.

@en

Cannabinoid CB2 receptor agoni ...... ance for Huntington's disease.

@nl

type

label

Cannabinoid CB2 receptor agoni ...... ance for Huntington's disease.

@en

Cannabinoid CB2 receptor agoni ...... ance for Huntington's disease.

@nl

prefLabel

Cannabinoid CB2 receptor agoni ...... ance for Huntington's disease.

@en

Cannabinoid CB2 receptor agoni ...... ance for Huntington's disease.

@nl

P1433

Q37253331-B037CC0F-8FD4-43B1-8372-0460B04A1D9C

P1476

Q37253331-AC409F25-0CE7-4AA2-BEA2-35B12AEAE597

P2093

Q37253331-0E7C30CA-6198-4856-9DDB-93013AC0C929

Q37253331-29223307-A020-4B31-B88B-E187A70AA0AF

Q37253331-3B8760FD-C195-4A67-A063-7F930937C6A5

Q37253331-84FBF410-D031-4E40-94FD-F38DBEE2E582

Q37253331-8519A701-EC1A-4E08-9C8F-8D77C76DE181

Q37253331-8C4C899A-B415-4608-B662-D9A2CA1E3A89

Q37253331-CD484738-E992-432E-8463-9777B3684D9C

Q37253331-FED532E6-D1B8-487D-92D5-D9BE9D33A1FD

P2860

Q37253331-009BE6F2-FC96-4F0A-8E2B-145D661EE5DE

Q37253331-08AE623F-9324-417E-87B8-20FA4D91102A

Q37253331-09375EEA-A1A3-4FB4-80DA-0CD0371649A0

Q37253331-102954DB-6E45-476F-87E0-C8D9449757E3

Q37253331-11E512C5-802B-4B59-BD20-72707240AD8F

Q37253331-11F3644C-7DD6-4D45-8F73-9C0E3092305B

Q37253331-1A27F62B-F011-4D2A-B239-737D4F151E6E

Q37253331-1AE9E915-6B31-4A0C-A490-39497B1E9A78

Q37253331-1BAEFC52-7E5A-4E4E-B023-961FE65B5582

Q37253331-1DC2E0F8-2DCF-45E3-B7B2-A0240A1893A3

P304

Q37253331-A74E2C26-E09D-4157-A67F-E889D850BE93

P31

Q37253331-2A8B6C38-B2FC-4DB1-AC49-889144880161

P356

Q37253331-21FC2D45-5A4F-4CC0-B43D-3A165309E506

P433

Q37253331-E280CD52-035F-4231-80C7-4834F80F4EE8

P478

Q37253331-00E9C6BB-F80C-4FED-9B6A-7C651D441881

P50

Q37253331-31FCEAF7-29A9-4F32-8A28-4B5CAFE7DE1F

Q37253331-9E4D1B40-1EF4-4F19-936B-2A0375D6C5A9

Q37253331-E76BAF4B-72F1-4966-AE06-95B6BDE847BF

Q37253331-F1568361-F6B7-4C46-A81B-77F90EFAF2A0

P577

Q37253331-13B75E00-6865-4C2D-8B04-8A066D230B63

P5875

Q37253331-F2278BA8-7339-43E5-BC24-FB7A525C9C5B

P698

Q37253331-33983B6A-9319-49D7-8473-C62645ADD455

P921

Q37253331-205abee2-9787-4b7a-b278-e86cf828c0a7

Q37253331-8CC05C13-107F-43D1-9A7C-B6E1991FB740

Q37253331-C4380407-F0A6-44A2-AD70-D638C8FA0CA2

Q37253331-F3FD6243-89BE-4FFE-AE83-25CE12E2D492

Q37253331-FD36B9DD-3CE2-47EC-8CED-23119F4BC025

P932

Q37253331-70F7D044-B4F4-4E64-B2F6-17CEC711B954

P356

P1433

P1476

Cannabinoid CB2 receptor agoni ...... vance for Huntington's disease

@en

P2093

Cristina Benito

http://www.w3.org/2001/XMLSchema#string

Ilia Aroyo

http://www.w3.org/2001/XMLSchema#string

Javier Fernández-Ruiz

http://www.w3.org/2001/XMLSchema#string

Juan P Romero

http://www.w3.org/2001/XMLSchema#string

Julián Romero

http://www.w3.org/2001/XMLSchema#string

Raphael Mechoulam

http://www.w3.org/2001/XMLSchema#string

Rosa M Tolón

http://www.w3.org/2001/XMLSchema#string

Sara González

http://www.w3.org/2001/XMLSchema#string

P2860

Protein measurement with the Folin phenol reagent

Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation

The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset

Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor

Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains

Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism

Normal huntingtin function: an alternative approach to Huntington's disease

Huntington's disease

HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor

Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1)

P304

1154-1167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/GLIA.20838

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Emmanuel Brouillet

Isabel Lastres-Becker

Onintza Sagredo

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23712590

http://www.w3.org/2001/XMLSchema#string

P698

19115380

http://www.w3.org/2001/XMLSchema#string

P921

corpus striatum

Huntington disease

cannabinoid receptor

P932

2706932

http://www.w3.org/2001/XMLSchema#string